No CrossRef data available.
Article contents
Possible Antipsychotic Effect of Fluvoxamine
Published online by Cambridge University Press: 07 November 2014
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Letter to the Editor
- Information
- Copyright
- Copyright © Cambridge University Press 2005
References
REFERENCES
1.Stahl, SM. Antidepressant treatment of psychotic major depression: potential role of the σ receptor. CNS Spectr. 2005;10:519–523.CrossRefGoogle ScholarPubMed
2.Levkovitz, Y, Bloch, Y, Kaplan, D, Diskin, A, Abramovitchi, I. Fluvoxamine for psychosis in Alzheimer's disease. J Nerv Ment Dis. 2001;189:126–129.Google Scholar
1.Stahl, SM. Antidepressant treatment of major depression: potential role of the σ receptor. CNS Spectr 2005;10:319–323.Google Scholar
2.Stahl, SM. Not so selective serotonin reuptake inhibitors. J Clin Psychiatry. 1998;59:343–344.Google ScholarPubMed
3.Stahl, SM. Using secondary binding properties to select a not so selective serotonin reuptake inhibitor. J Clin Psychiatry. 1998;59:642–643.CrossRefGoogle Scholar
4.Stahl, SM. Selectivity of SSRIs: individualizing patient care through rational treatment choices. Int J Psy Clin Prac. 2004;8(suppl 1):3–10.CrossRefGoogle ScholarPubMed
5.Stahl, SM. Let them eat generics: can one atypical antipsychotic substitute for another? PsychEd Up. 2005;1:6–7.Google Scholar
6.Stahl, SM, Shayegan, DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):6–12.Google ScholarPubMed
7.Shayegan, DK, Stahl, SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr. 2004;9(suppl 11):6–14.CrossRefGoogle ScholarPubMed
You have
Access